CLN-617

N/A

Report date: 2024/05/03 20:00:50
First In Class

Base Information

Drug NameCLN-617
Drug Alias NameCLN-617
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor agonistsInterleukin-12 receptor stimulants
TargetsInterleukin-2 receptorInterleukin-12 receptor
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCullinan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A